ループス治療の世界市場：疾患タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別

世界のループス治療の市場規模は、2025年には35億5,000万米ドルと推定され、2032年には65億3,000万米ドルに達すると予測され、2025年～2032年にCAGR9.1%で成長する見込みです。

図.ループス治療市場シェア（%）、2025年、地域別

世界のループス治療市場は、世界のループス疾患の有病率の上昇により、過去数年間着実に成長しています。ループスは、身体の免疫系が自身の組織や臓器を攻撃し始める慢性の自己免疫疾患です。一般に出産適齢期の女性が罹患し、主な症状には関節痛、発疹、疲労、臓器の炎症などがあります。推定によると、約150万人のアメリカ人と少なくとも500万人の世界中の人々がループスに苦しんでいます。ループスの早期診断と治療に関する政府やヘルスケア組織による啓発活動の高まりが、市場の成長をさらに後押ししています。さらに、より安全で効果的な治療薬を開発するための研究が進められていることも、予測期間中の市場成長を後押ししています。

市場力学：

世界のループス治療市場は、世界のループス有病率の増加、ループスに関する啓発活動の高まり、ヘルスケア支出の増加によって牽引されています。米国ループス財団によると、米国では毎年約1万6,000人の新規患者が報告されています。ループス治療薬に焦点を当てた研究開発活動に対する政府の好意的な支援も、市場の成長を後押ししています。しかし、高い治療費と臓器特異的ループス治療薬の不足は、市場の成長をある程度抑制すると予想される主な要因の一部です。一方、新規の生物学的製剤や個別化医療に関する臨床試験が進行中であるため、今後数年間は市場参入者にとって有利な機会がもたらされる見通しです。

本調査の主な特徴

• 当レポートでは、世界のループス治療市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模とCAGR%を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
• 世界のループス治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 主要企業には、Hikma Pharmaceuticals PLC、Dr. Reddy's Laboratories Ltd.、Amgen Inc.、Novartis AG、Sanofi、UCB S.A.、ImmuPharma PLC、Bayer AG、Merck &Co.、Aurinia Pharmaceuticals Inc.、Pfizer Inc.、AstraZeneca、F.Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、Teva Pharmaceutical Industries Ltd.、武田薬品工業、Boehringer Ingelheim International Gmbhなどがあります。
• 本レポートの洞察により、マーケティング担当者や各企業の経営陣は、将来の製品上市、タイプのアップグレード、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。
• 世界のループス治療市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界のループス治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 疫学
• 市場動向
• 主な発展
• 規制シナリオ
• メーカー収益
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界のループス治療市場：COVID-19パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界のループス治療市場：疾患タイプ別（2020年～2032年）

• 全身性エリテマトーデス（SLE）
• 皮膚エリテマトーデス
• 薬剤誘発性エリテマトーデス
• 新生児ループス

第6章 世界のループス治療市場：治療タイプ別（2020年～2032年）

• 非ステロイド性抗炎症薬（NSAID）
• 生物学的製剤
• 抗マラリア薬
• コルチコステロイド
• その他

第7章 世界のループス治療市場：投与経路別（2020年～2032年）

• 経口
• 皮下
• 静脈内
• その他

第8章 世界のループス治療市場：流通チャネル別（2020年～2032年）

• 院内薬局
• 医療用品店
• その他

第9章 世界のループス治療市場：地域別（2020年～2032年）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB SA
  • ImmuPharma PLC
  • Bayer AG
  • Merck &Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • F.Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

第11章 アナリストの推奨事項

• 運命の輪
• アナリストの見解
• Coherent Opportunity Map（COM）

第12章 参考文献と調査手法

• 参考文献
• 調査手法

Global Lupus Therapeutic Market is estimated to be valued at USD 3.55 Bn in 2025 and is expected to reach USD 6.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032.

Figure. Lupus Therapeutic Market Share (%), By Region 2025

The global lupus therapeutic market has been witnessing steady growth over the past few years owing to the rising prevalence of lupus disease globally. Lupus is a chronic autoimmune disorder where the immune system of the body starts attacking its own tissues and organs. It commonly affects women in their childbearing years and major symptoms include joint pain, rashes, fatigue, and organ inflammation. According to estimates, about 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus. Growing awareness initiatives by government and healthcare organizations regarding early diagnosis and treatment of lupus has further boosted the market growth. Moreover, ongoing research into developing safer and more effective therapeutic drugs will continue driving the market growth during the forecast period.

Market Dynamics:

The global lupus therapeutic market is driven by the growing prevalence of lupus globally, rising awareness initiatives regarding the disease, and increasing healthcare expenditure. As per the Lupus Foundation of America, around 16,000 new cases are reported in the U.S. every year. Favorable government support for research and development activities focused on lupus therapeutics is also propelling the market growth. However, high treatment cost and lack of drugs for organ-specific lupus are some of the key factors expected to restrain the market growth to a certain extent. On the other hand, ongoing clinical trials for novel biologic drugs and personalized medicine offer lucrative opportunities for market players in the coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global lupus therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global lupus therapeutic market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market.

Detailed Segmentation-

• By Disease Type:
  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus
  • Drug-Induced Lupus Erythematosus
  • Neonatal Lupus
• By Treatment Type:
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Biologics
  • Antimalarial Drugs
  • Corticosteroids
  • Others
• By Route of Administration:
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Medical Stores
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hikma Pharmaceuticals PLC
  • Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB S.A.
  • ImmuPharma PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Epidemiology
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Lupus Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Lupus Therapeutic Market, By Disease Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Systemic Lupus Erythematosus (SLE)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cutaneous Lupus Erythematosus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Drug-Induced Lupus Erythematosus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neonatal Lupus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Lupus Therapeutic Market, By Treatment Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biologics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antimalarial Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Lupus Therapeutic Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Lupus Therapeutic Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Medical Stores
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Lupus Therapeutic Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Hikma Pharmaceuticals PLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB S.A.
  • ImmuPharma PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • F.Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact